3 Pharma Ingredients and Custom Manufacturing Company, Oleochemical Additives Maker and Formulations Exporter Stocks With a Strong Future Roadmap: Neuland Laboratories, Fine Organic Industries and Marksans Pharma
- November 2, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Neuland Laboratories, Fine Organic Industries and Marksans Pharma: ROE of 13.8% to 19.4% and FY22 to FY26 revenue CAGR of 6.8% to 21.1%. Prices as of 30 Oct 2026.
Quick Answer
The three API, additive chemical and generic drug stocks to watch are Neuland Laboratories, Fine Organic Industries and Marksans Pharma. Their return on equity ranges from 13.8% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.1%. Neuland Laboratories leads on both return on equity at 19.4% and revenue growth at 21.1% a year. Prices are based on the 30 October 2026 close, and this article is educational, not investment advice.
API, additive chemical and generic drug stocks offer a focused view of a sector where demand keeps widening. Neuland Laboratories, Fine Organic Industries and Marksans Pharma cover a pharma ingredients and custom manufacturing company, an oleochemical additives maker and a formulations exporter.
This list covers three API, additive chemical and generic drug stocks with complete current figures: Neuland Laboratories, Fine Organic Industries and Marksans Pharma. Every figure comes from the latest reported financials and the 30 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are API, Additive Chemical and Generic Drug Stocks?
API, additive chemical and generic drug stocks are listed companies that make active pharmaceutical ingredients and custom products, produce oleochemical based additives for food, plastics and cosmetics, and sell over the counter and prescription formulations overseas. Their earnings depend on export orders, product mix and input costs.
API, Additive Chemical and Generic Drug Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Neuland Laboratories | 19,700 | 24,665 | 49.5 | 36.0 | 19.4 | 0.16 |
| Fine Organic Industries | 5,049 | 16,561 | 37.8 | 35.1 | 15.7 | 0.03 |
| Marksans Pharma | 306.2 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
On valuation, Marksans Pharma trades at a P/E below the industry P/E, while Neuland Laboratories and Fine Organic Industries trade above it, which reflects the growth the market already expects. Readers comparing API, additive chemical and generic drug stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do API, Additive Chemical and Generic Drug Stocks Have a Strong Roadmap in India?
API, additive chemical and generic drug stocks have a strong roadmap in India because global drug makers adding Indian partners, steady demand for specialty additives and wider formulation exports keep widening the market for these companies.
- Global supply. Regulated markets buy Indian ingredients.
- Specialty additives. Niche products support pricing strength.
- Formulation exports. Branded and generic medicines reach many countries.
Why Neuland Laboratories Features Among These API, Additive Chemical and Generic Drug Stocks
Among the API, additive chemical and generic drug stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.
Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.
Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.
Why Fine Organic Industries Features Among These API, Additive Chemical and Generic Drug Stocks
Among the pharma and specialty chemistry shares on this list, Fine Organic Industries is a leading maker of oleochemical-based additives used in food, plastics, cosmetics and coatings, selling to customers in India and overseas.
In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%.
Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1.
Roadmap: The company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.
What to watch: Monitor raw material prices, export demand and the pace of new capacity addition.
Why Marksans Pharma Features Among These API, Additive Chemical and Generic Drug Stocks
Among the three companies on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Neuland Laboratories vs Fine Organic Industries vs Marksans Pharma on Key Financials
The table below sets the three API, additive chemical and generic drug stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Neuland Laboratories | 953 | 2,053 | 21.1% | 364 | 17.7% |
| Fine Organic Industries | 1,909 | 2,482 | 6.8% | 417 | 16.8% |
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
Neuland Laboratories posts the highest return on equity in this group at 19.4%. Marksans Pharma has the largest FY26 revenue at Rs 3,033 crore, and Neuland Laboratories shows the fastest revenue growth with a 21.1% compound annual rate. A useful habit with API, additive chemical and generic drug stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in API, Additive Chemical and Generic Drug Stocks
Every theme carries risks that deserve a check before any decision. For these API, additive chemical and generic drug stocks, the main points are: Long-term pharma and specialty chemistry shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter API, additive chemical and generic drug stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on API, Additive Chemical and Generic Drug Stocks
API, additive chemical and generic drug stocks reward patient research into demand, execution and financial strength. Neuland Laboratories, Fine Organic Industries and Marksans Pharma each have a clear plan to grow. Based on the 30 October 2026 close, Neuland Laboratories trades at Rs 19,700, Fine Organic Industries at Rs 5,049 and Marksans Pharma at Rs 306.2. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these API, additive chemical and generic drug stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track API, additive chemical and generic drug stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are API, additive chemical and generic drug stocks?
Ans. API, additive chemical and generic drug stocks are listed companies that make active pharmaceutical ingredients and custom products, produce oleochemical based additives for food, plastics and cosmetics, and sell over the counter and prescription formulations overseas. Their earnings depend on export orders, product mix and input costs. This list looks at three of them, Neuland Laboratories, Fine Organic Industries and Marksans Pharma, using reported FY22 to FY26 financials and the 30 October 2026 closing prices.
Which API, additive chemical and generic drug stocks are covered in this list?
Ans. This list covers Neuland Laboratories, Fine Organic Industries and Marksans Pharma. Based on the 30 October 2026 close, Neuland Laboratories traded at Rs 19,700, Fine Organic Industries at Rs 5,049 and Marksans Pharma at Rs 306.2. Their return on equity ranges from 13.8% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 6.8% to 21.1%.
Why do API, additive chemical and generic drug stocks have a strong future roadmap in India?
Ans. API, additive chemical and generic drug stocks have a strong roadmap in India because global drug makers adding Indian partners, steady demand for specialty additives and wider formulation exports keep widening the market for these companies. The main drivers are as follows. Global supply. Regulated markets buy Indian ingredients. Specialty additives. Niche products support pricing strength. Formulation exports. Branded and generic medicines reach many countries. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Neuland Laboratories performed financially?
Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
How has Fine Organic Industries performed financially?
Ans. Revenue rose from Rs 1,909 crore in FY22 to Rs 2,482 crore in FY26, a compound annual growth rate of 6.8%. Net profit grew from Rs 260 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 12.6%. In the June 2026 quarter, revenue grew 14.4% year on year to Rs 718 crore, while net profit rose 18.0% to Rs 138 crore. The company has a return on equity of 15.7%, a debt to equity ratio of 0.03 and a market capitalisation of Rs 16,561 crore. The stock trades at a P/E of 37.8, above the industry P/E of 35.1. Looking ahead, the company holds a strong position in additives for plastics and food products and is adding capacity to meet export demand. A large net cash position and low debt give flexibility to invest in new product lines.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What risks should investors check before buying API, additive chemical and generic drug stocks?
Ans. Investors should check a few risks before buying API, additive chemical and generic drug stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of API, additive chemical and generic drug stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 30 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
